This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Enhancing Radioligand Therapy Efficacy through Rational Combination with DDR Inhibitors

Enhancing Radioligand Therapy Efficacy through Rational Combination with DDR Inhibitors

1:30 pm - Thursday 23rd July 2026

Exploring DNA damage synergy between alpha/beta emitters and DDR inhibitors to amplify tumor cell killing
Optimizing preclinical combination timing and sequencing to maximize efficacy while minimizing toxicity
Identifying biomarkers to guide patient selection and predict responsiveness in combination strategies

Speakers:

Marsela Braunstein

Radioconjugate Discovery Biology Lead

AstraZeneca